Rapport Therapeutics, Inc. RAPP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$107.28M-34.6% | -$111.48M-42.4% | -$97.7M-36.0% | -$88.31M-40.1% | -$79.7M-55.3% | ||
| $1M+7.4% | $1.02M+21.2% | $1.01M+60.1% | $975K+124% | $931K— | ||
| $21.78M+70.4% | $18.86M+84.2% | $16.37M+104% | $14.82M+160% | $12.78M— | ||
| —— | —— | —— | —— | —— | ||
| $4.51M— | $2.39M— | —— | —— | —— | ||
| $2.34M+350% | $6.17M+1,562% | $3.33M+14.8% | $1.95M-47.1% | $521K— | ||
| —— | —— | —— | $5.83M— | —— | ||
| $2.2M+146% | $2.03M+217% | $1.63M+158% | $1.22M— | $897K— | ||
| -$80.3M-19.0% | -$87.47M-34.9% | -$77.22M-27.1% | -$76.17M-53.1% | -$67.45M— | ||
| $411K-74.7% | $616K-74.4% | $673K-81.4% | $679K-80.8% | $1.62M— | ||
| $341.92M-9.1% | $354.78M-6.0% | $242.27M-22.4% | $250.39M+12.9% | $375.97M+266% | ||
| $161.69M-40.2% | $167.93M-20.0% | $261.73M— | $273.59M— | $270.41M— | ||
| -$170.56M— | -$187.47M— | —— | —— | —— | ||
| $2.15M+19,020% | $1.35M+19,157% | $643.75K+3,333% | $9.5K-68.9% | $11.25K-73.4% | ||
| —— | —— | —— | —— | —— | ||
| $271.31M+70.2% | $270.79M+21.4% | $270.48M— | -$51K— | $159.37M— | ||
| $20.45M— | -$4.16M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.34M+350% | $6.17M+1,562% | $3.33M+14.8% | $1.95M-47.1% | $521K— | ||
| $1.11M+90.4% | $500K-25.4% | $286K-56.2% | $455K— | $582K— | ||
| —— | —— | $878K+1,272% | $516K— | -$5K— | ||
| —— | —— | —— | $5.83M— | —— | ||
| $2.2M+146% | $2.03M+217% | $1.63M+158% | $1.22M— | $897K— | ||
| $161.69M-40.2% | $167.93M-20.0% | $261.73M— | $273.59M— | $270.41M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$80.71M-16.8% | -$88.09M-31.0% | -$77.89M-21.0% | -$76.85M-44.2% | -$69.07M— | ||
| -$80.71M-16.8% | -$88.09M-31.0% | -$77.89M-21.0% | -$76.85M-44.2% | -$69.07M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Rapport Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.